Get the Stockscreener App
39.52
3.43%
1.31
Travere Therapeutics Inc stock is traded at $39.52, with a volume of 1.71M.
It is up +3.43% in the last 24 hours and up +16.27% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$38.21
Open:
$39.11
24h Volume:
1.71M
Relative Volume:
0.94
Market Cap:
$3.54B
Revenue:
$333.87M
Net Income/Loss:
$-169.00M
P/E Ratio:
-19.37
EPS:
-2.04
Net Cash Flow:
$-157.30M
1W Performance:
-0.30%
1M Performance:
+16.27%
6M Performance:
+166.31%
1Y Performance:
+108.33%
1-Day Range:
$38.00
$40.19
1-Week Range:
$37.23
$40.19
52-Week Range:
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
39.52 | 3.42B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date - ts2.tech
Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4% Following Insider Selling - MarketBeat
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shift From Loss To Profit - 富途牛牛
Travere Therapeutics Insider Sold Shares Worth $2,406,180, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics (NASDAQ:TVTX) Insider Peter Heerma Sells 4,980 Shares - MarketBeat
Inrig Jula, chief medical officer of Travere, sells $630,004 in TVTX - Investing.com Canada
Travere therapeutics (TVTX) SVP Calvin sells $296k in stock By Investing.com - Investing.com Canada
Travere therapeutics (TVTX) chief research officer sells $2.4m in stock - Investing.com Canada
Heerma, Travere therapeutics CCO, sells $199k in TVTX stock By Investing.com - Investing.com Canada
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CAO Sells 7,402 Shares of Stock - MarketBeat
Why Travere Therapeutics stock popped by nearly 14% on Wednesday - MSN
Travere Therapeutics Inc. (TVTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Traders Buy Large Volume of Call Options on Travere Therapeutics (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally - ts2.tech
Voya Investment Management LLC Acquires 27,133 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Is Travere Therapeutics Still Attractively Priced After Its 135% Share Price Surge? - Yahoo Finance
Why Travere Therapeutics (TVTX) Is Up 18.9% After FDA Eases FILSPARI Oversight And Delays Adcom - Yahoo Finance
Travere Therapeutics (TVTX): Valuation Check After FDA Tailwinds and FSGS Expansion Hopes for FILSPARI - Yahoo! Finance Canada
Travere Stock (+14%): FDA Catalyst Speculation Ignites Rally - Trefis
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday - Finviz
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday - The Motley Fool
Travere Therapeutics Inducement Grants: Market Anticipations - StocksToTrade
Is Travere Therapeutics Stock a Hidden Gem? - timothysykes.com
Travere Therapeutics stock gains as FDA messaging on proteinuria endpoint boosts Filspari approval hopes - Investing.com Australia
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets - ts2.tech
Travere Therapeutics (TVTX) Shares Surge Over 16% - GuruFocus
Travere Therapeutics (TVTX) Surges on Positive FDA Update - GuruFocus
Travere Therapeutics Expands with New Employee Stock Grants - timothysykes.com
Travere Therapeutics (TVTX) Sees a Significant 13.2% Surge - GuruFocus
Travere Therapeutics (NASDAQ:TVTX) Reaches New 52-Week HighHere's Why - MarketBeat
Travere Therapeutics stock hits 52-week high at 37.76 USD By Investing.com - Investing.com Nigeria
Travere Therapeutics stock hits 52-week high at 37.76 USD - Investing.com
Assenagon Asset Management S.A. Has $2.23 Million Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Biotech Stocks Facing FDA Decision In January 2026 - RTTNews
The Technical Signals Behind (TVTX) That Institutions Follow - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Is Travere Therapeutics Inc. stock a safe buy before earningsJuly 2025 PreEarnings & Consistent Growth Stock Picks - Улправда
Is Travere Therapeutics Inc. stock a contrarian buyEarnings Trend Report & Fast Exit Strategy with Risk Control - Улправда
Can Travere Therapeutics Inc. stock double in next 5 yearsGlobal Markets & Verified Entry Point Detection - Улправда
Is Travere Therapeutics Inc stock a contrarian buy2025 Momentum Check & Community Trade Idea Sharing Platform - moha.gov.vn
Forecast Cut: How Travere Therapeutics Inc. stock trades during market volatility2025 Key Lessons & Real-Time Volume Spike Alerts - Улправда
How Travere Therapeutics Inc. stock reacts to Fed rate cutsStock Surge & Weekly Momentum Stock Picks - DonanımHaber
Will Travere Therapeutics Inc. stock maintain momentum in 2025July 2025 Pullbacks & Low Risk Investment Opportunities - DonanımHaber
Will Travere Therapeutics Inc. stock beat EPS estimates2025 Growth vs Value & Accurate Buy Signal Notifications - Улправда
How Travere Therapeutics Inc. stock trades during market volatility2025 Fundamental Recap & Daily Chart Pattern Signals - Улправда
Travere Therapeutics (TVTX) Gets a Buy from Evercore ISI - The Globe and Mail
Why Travere Therapeutics Inc. stock is seen as undervaluedMarket Volume Report & Capital Protection Trade Alerts - DonanımHaber
How Travere Therapeutics Inc. stock reacts to bond yieldsEntry Point & Reliable Intraday Trade Alerts - Улправда
IgA Nephropathy Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharma - Barchart.com
FY2025 Earnings Estimate for TVTX Issued By HC Wainwright - MarketBeat
Insider Sell: Sandra Calvin Sells Shares of Travere Therapeutics Inc (TVTX) - GuruFocus
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Travere Therapeutics Inc Stock (TVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROTE WILLIAM E. | Chief Research Officer |
Dec 24 '25 |
Option Exercise |
20.61 |
60,000 |
1,236,600 |
161,443 |
| ROTE WILLIAM E. | Chief Research Officer |
Dec 24 '25 |
Sale |
40.10 |
60,000 |
2,406,180 |
101,443 |
| Inrig Jula | CHIEF MEDICAL OFFICER |
Dec 24 '25 |
Option Exercise |
8.93 |
15,000 |
133,950 |
103,787 |
| Inrig Jula | CHIEF MEDICAL OFFICER |
Dec 24 '25 |
Sale |
42.00 |
15,000 |
630,004 |
88,787 |
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER |
Dec 24 '25 |
Sale |
40.00 |
7,402 |
296,080 |
38,233 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):